Unlock stock picks and a broker-level newsfeed that powers Wall Street.
IOB - Delayed Quote EUR

Virbac SA (0NM7.IL)

Compare
295.50
-9.50
(-3.11%)
At close: April 4 at 5:36:19 PM GMT+1
Loading Chart for 0NM7.IL
  • Previous Close 305.00
  • Open 303.50
  • Bid 292.00 x --
  • Ask 297.50 x --
  • Day's Range 293.00 - 303.50
  • 52 Week Range 290.50 - 399.00
  • Volume 343
  • Avg. Volume 443
  • Market Cap (intraday) 2.518B
  • Beta (5Y Monthly) 0.90
  • PE Ratio (TTM) 21.12
  • EPS (TTM) 13.99
  • Earnings Date Mar 13, 2025
  • Forward Dividend & Yield 1.32 (0.52%)
  • Ex-Dividend Date Jun 26, 2023
  • 1y Target Est --

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.

corporate.virbac.com

5,386

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 0NM7.IL

View More

Performance Overview: 0NM7.IL

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

0NM7.IL
6.34%
CAC 40 (^FCHI)
1.43%

1-Year Return

0NM7.IL
16.86%
CAC 40 (^FCHI)
10.75%

3-Year Return

0NM7.IL
18.99%
CAC 40 (^FCHI)
8.08%

5-Year Return

0NM7.IL
83.89%
CAC 40 (^FCHI)
75.11%

Compare To: 0NM7.IL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0NM7.IL

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    2.46B

  • Enterprise Value

    2.62B

  • Trailing P/E

    17.04

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.77

  • Price/Book (mrq)

    2.37

  • Enterprise Value/Revenue

    1.87

  • Enterprise Value/EBITDA

    9.47

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.87%

  • Return on Assets (ttm)

    8.00%

  • Return on Equity (ttm)

    13.80%

  • Revenue (ttm)

    1.21B

  • Net Income Avi to Common (ttm)

    119.2M

  • Diluted EPS (ttm)

    13.99

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    224.3M

  • Total Debt/Equity (mrq)

    18.78%

  • Levered Free Cash Flow (ttm)

    68.55M

Research Analysis: 0NM7.IL

View More

Company Insights: 0NM7.IL

Research Reports: 0NM7.IL

View More

People Also Watch